Online citations, reference lists, and bibliographies.

Therapeutic Mechanisms Of Classic Hallucinogens In The Treatment Of Addictions: From Indirect Evidence To Testable Hypotheses.

M. Bogenschutz, Jessica M Pommy
Published 2012 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Alcohol and drug addiction are major public health problems, and existing treatments are only moderately effective. Although there has been interest for over half a century in the therapeutic use of classic hallucinogens to treat addictions, clinical research with these drugs was halted at an early stage in the early 1970s, leaving many fundamental questions unanswered. In the past two decades, clinical research on classic hallucinogens has resumed, although addiction treatment trials are only now beginning. The purpose of this paper is to provide a targeted review of the research most relevant to the therapeutic potential of hallucinogens, and to integrate this information with current thinking about addiction and recovery. On the basis of this information, we present a heuristic model which organizes a number of hypotheses that may be tested in future research. We conclude that existing evidence provides a convincing rationale for further research on the effects of classic hallucinogens in the treatment of addiction.
This paper references
10.1001/jama.1970.03170240060010
The experimental use of psychedelic (LSD) psychotherapy.
W. Pahnke (1970)
10.1111/J.1530-0277.1996.TB01686.X
A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment.
D. I. Kabel (1996)
10.1007/978-1-4899-1678-5_13
Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers.
C. Naranjo (1989)
Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
N. Buckholtz (1990)
10.1038/sj.npp.1300711
Behavioral Tolerance to Lysergic Acid Diethylamide is Associated with Reduced Serotonin-2A Receptor Signaling in Rat Cortex
P. Gresch (2005)
10.1016/S0084-3970(08)70128-2
Prevalence and Co-occurrence of Substance Use Disorders and Independent Mood and Anxiety Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions
J. Talbott (2006)
10.1176/ajp.125.10.1352
A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics.
L. Hollister (1969)
10.1016/J.JEP.2005.04.022
Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas.
H. El-Seedi (2005)
10.1080/02791072.1977.10472060
Psychedelic Drug (DPT)-Assisted Psychotherapy with Alcoholics: A Controlled Study
J. Rhead (1977)
10.1016/J.DRUGALCDEP.2004.09.004
Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis.
M. Torrens (2005)
Wilbourne. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders
P.L.W.R. Miller (2002)
The effects of psychedelic (LSD) therapy on values, personality, and behavior.
C. Savage (1966)
10.1001/ARCHPSYC.1997.01830200024004
Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial.
J. Cornelius (1997)
10.2307/1906744
Peyote Religion: A History
O. Stewart (1987)
10.1186/1471-244X-8-22
Five-Factor Model personality profiles of drug users
A. Terracciano (2008)
10.1016/0006-3223(94)91215-7
Serotonin and alcohol intake, abuse, and dependence: Findings of animal studies
D. Lemarquand (1994)
10.1016/S0006-3223(99)00230-9
Antidepressant effects of ketamine in depressed patients
R. Berman (2000)
10.1177/0960327107087802
Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review
R. Mačiulaitis (2008)
Alcoholics Anonymous and Other 12-Step Groups
C. Emrick (1999)
10.1016/j.biopsych.2007.05.028
Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors
S. Maeng (2008)
10.1111/j.1749-6632.1998.tb08242.x
Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependencea.
D. Mash (1998)
Psilocybin in smoking cessation: A pilot study
M. W. Johnson (2010)
10.1007/s00213-002-1002-9
Ondansetron reduces the craving of biologically predisposed alcoholics
B. Johnson (2002)
10.1111/J.1360-0443.2006.01423.X
A review of the acute subjective effects of MDMA/ecstasy.
Chelsea A. Baylen (2006)
10.15288/JSAD.2007.68.641
Cocaine craving as a predictor of treatment attrition and outcomes after residential treatment for cocaine dependence.
D. Rohsenow (2007)
10.1177/0013124582015001005
Counseling
Joan P. Avis (1982)
Possible pharmacological probes for predicting and preventing relapse in treated alcoholics.
Naranjo Ca (1991)
10.1093/CERCOR/13.8.870
In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents.
M. Puig (2003)
10.1016/S0278-5846(03)00081-2
Drug craving and addiction: integrating psychological and neuropsychopharmacological approaches
I. Franken (2003)
10.1080/09595230601036960
Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications.
R. Sinha (2007)
10.1300/J020v21n04_02
Life-Changing Experiences, Spirituality and Religiousness of Persons Entering Treatment for Alcohol Problems
E. Robinson (2003)
10.1177/0269881108094300
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
R. Griffiths (2008)
Counseling
W. A. Richards (2012)
10.1097/00005053-197002000-00003
LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW‐UP STUDY
W. Bowen (1970)
10.1016/S0893-133X(98)00108-0
5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride
F. Vollenweider (1999)
10.1080/02791072.2007.10399860
Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence
E. Krupitsky (2007)
10.1177/009164718301100406
Spiritual Well-Being: Conceptualization and Measurement
C. W. Ellison (1983)
10.15288/JSA.2006.67.562
Examining the effects of alcoholism typology and AA attendance on self-efficacy as a mechanism of change.
M. Bogenschutz (2006)
10.1093/SHM/HKL039
‘Hitting Highs at Rock Bottom’: LSD Treatment for Alcoholism, 1950–1970
E. Dyck (2006)
10.1080/00221309.1969.9710481
Personality change in LSD users.
John Bottrill (1969)
10.1177/0269881112439253
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
T. S. Krebs (2012)
A program for treatment of alcoholism: LSD
A. Hoffer (1967)
10.1111/J.1530-0277.2007.00499.X
A role for spiritual change in the benefits of 12-step involvement.
S. Zemore (2007)
10.1001/ARCHPSYC.63.8.856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
C. Zarate (2006)
10.1177/0269881106063271
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
G. Dumont (2006)
What is motivational interviewing? Behav
S. Rollnick (1995)
10.15288/qjsa.1970.31.932
Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation.
M. Tomsovic (1970)
10.1080/02791072.1968.10524522
The psychedelic experience--a new concept in psychotherapy.
J. N. Sherwood (1962)
10.1037/h0088594
Personality change associated with psychedelic (LSD) therapy: A preliminary report.
R. Mogar (1964)
10.2190/DE.37.3.d
Alcohol Involvement and the Five-Factor Model of Personality: A Meta-Analysis
J. Malouff (2007)
10.2307/1384454
The Construction and Preliminary Validation of a Measure of Reported Mystical Experience
R. W. Hood (1975)
10.1525/maq.1983.14.2.02a00120
Food Safety Program at WHO
George M. Foster (1983)
10.1300/J069v25n04_06
Personality Changes in Women Recovering from Substance-Related Dependence
Patricia D. Borman (2006)
10.4324/9780203393789
Varieties of Religious Experience
W. James (1990)
10.1111/J.1749-6632.2000.TB06677.X
Development of novel medications for drug addiction. The legacy of an African shrub.
S. Glick (2000)
10.1016/S0084-3970(10)79416-0
From In-Session Behaviors to Drinking Outcomes: A Causal Chain for Motivational Interviewing
R. Frances (2011)
10.1192/bjp.bp.110.084178
Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [¹¹C]raclopride study in humans.
S. Cox (2011)
The adverse effects of hallucinogens from intramural perspective.
E. Frecska (2006)
Medications and Alcohol Craving
R. Swift (1999)
10.1016/j.pbb.2007.10.003
Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons
G. Gudelsky (2008)
A review of LSD treatment in alcoholism.
F. Abuzzahab (1971)
Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.
J. Halpern (2008)
Pharmacology of classical hallucinogens and related designer drugs
R. A. Glennon (2009)
10.1038/tp.2011.57
Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption
S. Barak (2011)
10.1001/archpsyc.1967.01730290009002
LONG LASTING EFFECTS OF LSD ON NORMALS
W. Mcglothlin (1967)
10.1016/j.biopsych.2008.09.029
Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist
L. Phelps (2009)
10.1016/S0306-4603(98)00005-7
The relationship of NEO-PI performance to coping styles, patterns of use, and triggers for use among substance abusers.
R. McCormick (1998)
10.1177/0269881108093587
Human hallucinogen research: guidelines for safety
M. Johnson (2008)
Mysticaltype experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months
R. Griffiths (2008)
10.4135/9781412964500.n199
Motivational interviewing.
A. Gibson (2000)
10.1016/j.neubiorev.2011.03.005
5-HT receptors and reward-related behaviour: A review
D. Hayes (2011)
Religion and Psychoactive Sacraments: A Bibliographic Guide
T. B. Roberts (1995)
10.1037//0893-164X.14.3.257
Alcohol treatment, changes in coping skills, self-efficacy, and levels of alcohol use and related problems 1 year following treatment initiation.
S. Maisto (2000)
10.1186/1471-244X-3-1
Relationship between craving and personality in treatment-seeking women with substance-related disorders
M. Zilberman (2003)
Life Changing Experiences: An Analysis of 21st Century Martin Amis
Julia van Luijk (2011)
10.1176/appi.ajp.2010.10050755
Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
B. Johnson (2011)
Religion and Psychoactive Sacraments: A Bibliographic Guide
T. B. Roberts (1995)
10.1016/j.psychres.2004.07.013
Impact of different personality dimensions (NEO Five-Factor Inventory) on the outcome of alcohol-dependent patients 6 and 12 months after treatment
M. Bottlender (2005)
10.1371/journal.pone.0014074
Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans
M. Baggott (2010)
10.1016/j.comppsych.2008.09.003
Comorbidity and temporal ordering of alcohol use disorders and other psychiatric disorders: results from a Danish register-based study.
T. Flensborg-Madsen (2009)
10.1006/JRPE.2001.2326
Cracking the plaster cast: Big five personality change during intensive outpatient counseling.
R. Piedmont (2001)
10.1073/pnas.0708862105
Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo
C. L. Schmid (2008)
10.1016/J.BCP.2007.08.005
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
B. Johnson (2008)
10.1016/j.drugalcdep.2010.03.024
Assessment of addiction severity among ritual users of ayahuasca.
Josep María Fábregas (2010)
10.1016/S0740-5472(02)00275-1
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.
E. Krupitsky (2002)
10.1176/ajp.152.3.391
Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics.
H. Kranzler (1995)
10.1016/j.pharmthera.2010.09.007
Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse.
G. Breese (2011)
10.1111/J.1530-0277.1996.TB05263.X
Efficacy of buspirone in alcohol dependence: a review.
T. Malec (1996)
10.1080/02791072.1998.10399709
Hallucinogenic drugs and plants in psychotherapy and shamanism.
R. Metzner (1998)
10.1080/02791072.2009.10399905
Changes in Spirituality Among Ayahuasca Ceremony Novice Participants
Stephen Trichter (2009)
10.1016/B978-0-12-385506-0.00010-7
Role of the serotonergic system in alcohol dependence: from animal models to clinics.
Y. Sari (2011)
10.5860/choice.35-1826
Self-Efficacy: The Exercise of Control
A. Bandura (1997)
10.1037/h0041593
Cognitive consequences of forced compliance.
L. Festinger (1959)
10.1176/appi.psychotherapy.1964.18.1.35
LSD IN PSYCHOTHERAPY.
S. Schoen (1964)
10.1037/a0020327
Linking "big" personality traits to anxiety, depressive, and substance use disorders: a meta-analysis.
R. Kotov (2010)
10.1007/s00127-003-0597-4
Temporal sequencing of lifetime mood disorders in relation to comorbid anxiety and substance use disorders
R. de Graaf (2003)
10.1159/000467979
DPT as an adjunct in psychotherapy of alcoholics.
S. Grof (1973)
Theroetical aspects of LSD therapy
J. Buckman (1967)
10.1111/j.1465-3362.2011.00303.x
Relationship of relapse with impulsivity, novelty seeking and craving in male alcohol-dependent inpatients.
C. Evren (2012)
10.1016/j.biopsych.2004.05.009
Treatment of cocaine dependence and depression
B. Rounsaville (2004)
10.1097/00004850-199409000-00004
Fluoxetine attenuates alcohol intake and desire to drink
C. Naranjo (1994)
10.1038/nrn2884
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
F. Vollenweider (2010)
10.1080/02791072.2005.10399794
Report on Psychoactive Drug Use Among Adolescents Using Ayahuasca Within a Religious Context
Evelyn Doering-Silveira (2005)
10.1016/j.neulet.2011.01.046
Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists
J. L. Moreno (2011)
10.1176/ajp.126.1.59
A clinical study of LSD treatment in alcoholism.
A. Ludwig (1969)
10.1097/00005053-196312000-00007
REACTIONS TO PSILOCYBJN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT
T. Leary (1963)
Peyote Hunt
B. Meyerhoff (1974)
10.1300/J020v21n01_01
The Role of Religion, Spirituality and Alcoholics Anonymous in Sustained Sobriety
L. Kaskutas (2003)
A consensus statement on defining change talk
W. R. Miller (2006)
10.4414/SMW.2007.11932
Ketamine and the potential role for rapid-acting antidepressant medications.
J. Krystal (2007)
10.1002/JCLP.20000
The phenomenon of quantum change.
W. Miller (2004)
Motivation for Change and Alcoholism Treatment
C. Diclemente (1999)
Psychedelic Drugs Reconsidered
J. Bakalar (1979)
My First Forty Years
B. Wilson (2000)
10.1016/j.pharmthera.2008.12.001
GDNF--a potential target to treat addiction.
Sebastien Carnicella (2009)
10.1016/S0740-5472(03)00118-1
Exploratory findings from the Reasons for Drinking Questionnaire.
W. Zywiak (2003)
10.1016/j.biopsych.2009.08.038
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
M. A. Rot (2010)
10.1111/j.1369-1600.2008.00136.x
Identifying the neural circuitry of alcohol craving and relapse vulnerability
A. Heinz (2009)
10.1016/j.neuron.2007.01.008
Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior
J. González-Maeso (2007)
10.1080/00332747.1963.11023344
Mescaline, LSD, Psilocybin, and Personality Change a Review†
S. Unger (1963)
10.1525/MAQ.2000.14.4.521
Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing.
J. Garrity (2000)
10.1300/J020V09N01_09
The Combination of Psychedelic and Aversive Approaches in Alcoholism Treatment
E. M. Krupitsky (1992)
10.1007/S11920-007-0063-1
The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects
S. Maeng (2007)
10.2307/2217211
Mysticism and Philosophy.
N. Smart (1960)
Medication development of ibogaine as a pharmacotherapy for drug dependence.
D. Mash (1998)
10.4135/9781412953948.n413
Self efficacy.
B. Ootim (2000)
10.1523/JNEUROSCI.17-22-08828.1997
The Olivocerebellar Projection Mediates Ibogaine-Induced Degeneration of Purkinje Cells: A Model of Indirect, Trans-Synaptic Excitotoxicity
E. O'Hearn (1997)
10.1016/j.psychres.2005.05.005
Quantitative electroencephalographic measures in homicidal men with antisocial personality disorder
N. Lindberg (2005)
10.1523/JNEUROSCI.1665-10.2010
Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo
C. L. Schmid (2010)
10.1016/j.biopsych.2009.04.029
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
R. B. Price (2009)
10.1001/JAMA.291.15.1887
Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.
E. Nunes (2004)
10.1192/bjp.bp.107.041228
Brain dopamine response in human opioid addiction.
M. Daglish (2008)
10.1037/0022-3514.93.6.1080
Relations between personality and coping: a meta-analysis.
Jennifer K Connor-Smith (2007)
10.15288/qjsa.1966.27.469
A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior.
R. Smart (1966)
10.1007/s00213-011-2358-5
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
R. Griffiths (2011)
10.1016/j.arcped.2012.01.013
[Et al].
P. Cochat (2012)
10.4088/JCP.V67N1110
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
F. Moreno (2006)
10.1111/j.1360-0443.2011.03593.x
Determining the relative importance of the mechanisms of behavior change within Alcoholics Anonymous: a multiple mediator analysis.
J. Kelly (2012)
10.1111/J.1530-0277.2000.TB04648.X
Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype.
H. Pettinati (2000)
10.1111/j.1471-4159.2008.05357.x
Serotonin (5‐HT) induces glial cell line‐derived neurotrophic factor (GDNF) mRNA expression via the transactivation of fibroblast growth factor receptor 2 (FGFR2) in rat C6 glioma cells
M. Tsuchioka (2008)
10.1073/pnas.0700436104
Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex
Jean-Claude Béı̈que (2007)
10.1016/j.drugalcdep.2009.07.016
Reactivity to laboratory stress provocation predicts relapse to cocaine.
S. Back (2010)
10.1207/S15473333THP3404_7
Ketamine Enhanced Psychotherapy: Preliminary Clinical Observations on Its Effectiveness in Treating Alcoholism
E. Kolp (2006)
10.1080/00952990701653818
A Comparison of General Self-Efficacy and Drinking Refusal Self-Efficacy in Predicting Drinking Behavior
T. Oei (2007)
10.1080/02791072.1998.10399714
Treatment of alcoholism using psychedelic drugs: a review of the program of research.
M. Mangini (1998)
10.1002/JCLP.20004
De profundis: spiritual transformations in Alcoholics Anonymous.
A. Forcehimes (2004)
10.1037/a0025204
Dynamic effects of craving and negative affect on adolescent smoking relapse.
Rinka M P van Zundert (2012)
10.1097/00001756-199812010-00024
Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action
F. Vollenweider (1998)
10.1007/springerreference_121662
Glial Cell Line-Derived Neurotrophic Factor
Zoologie (2011)
10.1046/j.1360-0443.1995.9018712.x
Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems.
C. Naranjo (1995)
10.1017/S1461145709000169
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
S. Mathew (2010)
10.1159/000468273
A review of LSD treatment in alcoholism.
A. Fs (1971)
10.1300/J069v25n02_02
Relationship Between Plasma Cortisol Levels, Withdrawal Symptoms and Craving in Abstinent and Treated Heroin Addicts
F. Nava (2006)
10.3109/16066359609010756
The Use of Hallucinogens in the Treatment of Addiction
J. Halpern (1996)
10.1016/S0084-3970(08)79204-1
GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse
J. Ballenger (2009)
10.1016/j.neubiorev.2009.11.009
Role of BDNF and GDNF in drug reward and relapse: A review
U. Ghitza (2010)
Self-efficacy
A. Bandura (1994)
10.1001/JAMA.284.8.963
Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
B. Johnson (2000)
10.1111/1467-9280.00137
Motivation for Change: Implications for Substance Abuse Treatment
C. Diclemente (1999)
10.1111/j.1530-0277.2010.01362.x
Spirituality in recovery: a lagged mediational analysis of alcoholics anonymous' principal theoretical mechanism of behavior change.
J. Kelly (2011)
10.1016/j.addbeh.2011.07.032
The role of self-efficacy in the treatment of substance use disorders.
R. Kadden (2011)
10.1016/j.addbeh.2010.06.008
A personality-based description of maturing out of alcohol problems: extension with a five-factor model and robustness to modeling challenges.
Andrew K Littlefield (2010)
10.1176/ajp.131.11.1247
Peyote in the treatment of alcoholism among American Indians.
B. Albaugh (1974)
Five Factor correlates: A comparison of substance abusers and non-substance abusers
C. Dubey (2010)
Psychedelic drugs and mystical experience.
W. Pahnke (1969)
10.1111/j.1369-1600.2010.00251.x
Noribogaine, but not 18‐MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self‐administration
Sebastien Carnicella (2010)
10.1046/J.1360-0443.2002.00019.X
Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders.
W. Miller (2002)
10.1371/journal.pone.0010013
The Crystal Structure of PPIL1 Bound to Cyclosporine A Suggests a Binding Mode for a Linear Epitope of the SKIP Protein
C. Stegmann (2010)
10.1038/clpt.1992.85
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol‐dependent drinkers
C. Naranjo (1992)
10.1093/ALCALC/34.2.244
The role of serotonin in craving: from basic research to human studies.
R. Ciccocioppo (1999)
10.1037/a0022282
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
K. Witkiewitz (2011)
10.1080/00952990802455469
Traditional Medicine in the Treatment of Drug Addiction
Lin Lu (2009)
10.1016/j.biopsych.2005.06.038
Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans
J. Halpern (2005)
10.1111/J.1530-0277.2007.00390.X
Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study.
K. Yoder (2007)
10.1016/J.DRUGALCDEP.2004.08.025
High prevalence of substance use disorders among adolescents who use marijuana and inhalants.
Li-Tzy Wu (2005)
10.1177/0269881111420188
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
Katherine A. MacLean (2011)
10.1001/archgenpsychiatry.2010.116
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
C. Grob (2011)
10.1001/archpsyc.1973.01750360040005
Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study.
C. Savage (1973)
10.1073/pnas.0905884106
Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling
K. Jones (2009)
10.1016/0146-6402(78)90002-4
Self-efficacy: Toward a unifying theory of behavioral change
A. Bandura (1978)
10.1176/ajp.142.11.1259
The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence.
E. Khantzian (1987)
10.1037/0893-164X.10.2.90
A measure of religious background and behavior for use in behavior change research
G. Connors (1996)
10.1093/ALCALC/34.2.254
Craving and relapse measurement in alcoholism.
A. Potgieter (1999)
10.1016/j.drugalcdep.2009.03.009
Daily ratings measures of alcohol craving during an inpatient stay define subtypes of alcohol addiction that predict subsequent risk for resumption of drinking.
D. Oslin (2009)
10.15288/JSAD.2010.71.434
Negative affect, relapse, and Alcoholics Anonymous (AA): does AA work by reducing anger?
J. Kelly (2010)
10.1186/1471-244X-3-5
Measurement of illumination exposure in postpartum women
Emily J Wang (2003)
10.1523/JNEUROSCI.17-08-02785.1997
5-HT2A Receptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex
V. Vaidya (1997)
10.1371/journal.pone.0009019
Psychedelics and the Human Receptorome
Thomas S. Ray (2010)
10.1177/0269881110378371
The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
M. Mithoefer (2011)
10.1097/00005053-199612000-00009
Drinking Careers: A Twenty-Five-Year Study of Three Navajo Populations
P. Spicer (1996)
10.1016/j.pnpbp.2007.07.009
AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes
Ce Zhang (2008)
10.1300/J020v21n02_01
Alcoholics' Evaluations of Alcoholism Treatment
A. Mackenzie (2003)
10.1016/J.BCP.2007.07.018
The behavioral pharmacology of hallucinogens.
W. Fantegrossi (2008)
10.1038/mp.2008.41
Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions
B. Grant (2009)
Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical cons
W. Pahnke (1963)
Present state of psycholytic therap y and its possibilities
H. Leuner (1967)
10.1001/archgenpsychiatry.2010.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
N. Diazgranados (2010)
10.1007/s00213-006-0457-5
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
R. Griffiths (2006)
10.1037/0022-3514.84.2.411
Big Five factors of personality and replicated predictions of behavior.
S. Paunonen (2003)



This paper is referenced by
10.1177/0269881114565144
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
M. Bogenschutz (2015)
10.2174/15733998113099990003
Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada.
G. Thomas (2013)
10.1177/0269881113513851
Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision
P. Hendricks (2014)
Classic hallucinogens in the treatment of addictions F
Michael P. Bogenschutz (2015)
10.1007/978-3-642-40426-9_9
Effect of Santo Daime Membership on Substance Dependence
Beatriz Caiuby Labate (2014)
10.1002/dta.1974
Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.
Simon D Brandt (2017)
10.1097/FTD.0000000000000028
Potential therapeutic effects of psilocybin/psilocin are minimized while possible adverse reactions are overrated.
Rafael G. dos Santos (2014)
10.1016/j.pnpbp.2015.03.002
Classic hallucinogens in the treatment of addictions
M. Bogenschutz (2016)
10.1556/2054.2018.005
Psychedelic therapy as a complementary treatment approach for alcohol use disorders
Peter Eischens (2018)
10.1177/0269881118798610
The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women
Elena Argento (2018)
10.1016/B978-0-12-800212-4.00074-1
A Profile of Those Who Use Hallucinogenic Mushrooms
Mitchell G. Spring (2016)
10.25772/0YNR-6690
5-HT2B Receptor-mediated Cardiac Valvulopathy
Pallavi Nistala (2018)
10.2174/1874473708666150107120522
A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects.
Mitchell B. Liester (2014)
10.1177/2045125316640440
Lysergic acid diethylamide: a drug of ‘use’?
Saibal Das (2016)
10.1007/7854_2016_464
Therapeutic Applications of Classic Hallucinogens.
M. Bogenschutz (2018)
10.3389/fphar.2018.00897
Predicting Responses to Psychedelics: A Prospective Study
E. Haijen (2018)
10.1016/j.physbeh.2015.01.032
Effects of ayahuasca on the development of ethanol-induced behavioral sensitization and on a post-sensitization treatment in mice
A. J. Oliveira-Lima (2015)
10.1177/0269881118780612
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
Tehseen Noorani (2018)
10.1016/j.celrep.2018.05.022
Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly (2018)
10.1177/0022167816673493
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
M. Bogenschutz (2017)
10.1016/B978-0-12-410529-4.00108-X
Chapter 108 – Addiction
Scott D. Philibin (2015)
10.3109/00952990.2013.811513
A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment
Brittany Vasae Burdick (2013)
10.2174/1874473708666150107121331
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Albert Garcia-Romeu (2014)
10.1177/0269881117714049
Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness
Matthias Forstmann (2017)
Integrating Psilocybin and Existential-Humanistic Psychotherapy for Pathological Gambling Treatment: A New Perspective
T. Re (2019)
10.1016/j.neuropharm.2017.11.004
Why MDMA therapy for alcohol use disorder? And why now?
B. Sessa (2018)
10.1177/0269881116652578
The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging
R. D. Dos Santos (2016)
10.1177/0269881119845793
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia-Romeu (2019)
10.3389/fpsyt.2020.00497
Editorial: Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs?
F. Müller (2020)
10.1002/dta.1389
Research on psychedelic substances.
S. D. Brandt (2012)
10.1177/0269881114565653
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
P. Hendricks (2015)
10.1177/0269881114548296
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
M. Johnson (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar